• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    National Research Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    2/10/25 10:16:16 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email
    nrc20250207_8k.htm
    false 0000070487 0000070487 2025-02-06 2025-02-06
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________________________________________________
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported):
    February 6, 2025
    _______________________________________________________________________________
     
    National Research Corporation
    (Exact name of registrant as specified in its charter)
     
    Delaware
    001-35929
    47-0634000
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
     
    1245 Q Street, Lincoln, Nebraska
    68508
    (Address of principal executive offices)
    (Zip Code)
     
    (402) 475-2525
    (Registrant's telephone number, including area code)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    $.001 Par Value Common Stock NRC The NASDAQ Stock Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐    
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 1.01
    Entry into a Material Definitive Agreement.
     
     
     
    On February 6, 2025 (the “Closing Date”), National Research Corporation, a Delaware corporation (the “Company”), entered into a credit agreement (the “Credit Agreement”) with a group of lenders and First National Bank of Omaha, a national banking association, as agent, that amends and restates the terms of the Company’s existing credit facility dated May 28, 2020, as amended. The Credit Agreement provides for (i) a $30,000,000 revolving credit facility (the “Revolving Loan”) and (ii) a $110,000,000 delayed draw-down term facility (“the “Delayed Draw Term Loan” and, together with the Revolving Loan, the “Credit Facilities”). The Delayed Draw Term Loan includes an accordion feature that, so long as no event of default exists or would exist after giving effect to such increase, allows the Company to request an increase in the Delayed Draw Term Loan of up to the lesser of (x) $25,000,000 and (y) the Company’s EBITDA as of the preceding four fiscal quarters, exercisable in increments of $10,000,000 (or the remaining available amount of the accordion, if less).
     
     
     
    Principal amounts outstanding under the Revolving Loan are due and payable in full at maturity, which shall be the third anniversary of the Closing Date. The Revolving Loan will bear interest (which shall accrue and be due on a monthly basis during the term of the Revolving Loan) at a floating rate equal to the one-month Term SOFR (“Term SOFR”), plus a percentage per annum determined by the Company’s cash flow leverage ratio, ranging from 2.25% to 2.75%. As of Closing Date, there was approximately $3,500,000 outstanding under the Revolving Loan.
     
     
     
    Principal and accrued interest amounts outstanding under the Delayed Draw Term Loan are due and payable monthly during the term of the Delayed Draw Term Loan, which shall expire on the fifth anniversary of the Closing Date (the “Delayed Draw Term Loan Maturity Date”). The Delayed Draw Term Loan will bear interest at a floating rate equal to the Term SOFR, plus a percentage per annum determined by the Company’s cash flow leverage ratio, ranging from 2.25% to 2.75%. As of the Closing Date, the aggregate outstanding principal balance of the Delayed Draw Term Loan was $62,423,902.75 (the “Closing Date Principal Balance”). Principal amounts outstanding under the Delayed Draw Term Loan will be reduced by the following amortization schedule: (i) for the first, second, and third years following the date of such loan (or, in the case of the Closing Date Principal Balance, the first, second, and third years following the Closing Date), equal monthly installments sufficient to amortize the aggregate outstanding principal balance as of the date of such loan (or, in the case of the Closing Principal Balance, as of the Closing Date) by 5.00% and (ii) for the fourth and fifth years following the date of such loan (or, in the case of the Closing Date Principal Balance, the fourth and fifth years following the Closing Date), equal monthly installments sufficient to amortize the aggregate outstanding principal balance as of the date of such loan (or, in the case of the Closing Principal Balance, as of the Closing Date) by 7.50%. On the Delayed Draw Term Loan Maturity Date, all outstanding principal and accrued interest thereon will be due and payable in full.
     
     
     
    The Company is also obligated to pay ongoing unused commitment fees quarterly in arrears at a percentage per annum determined by the Company’s cash flow leverage ratio, ranging from 0.15% to 0.30%, based on the actual daily unused portions of the Revolving Loan and the Delayed Draw Term Loan, respectively.
     
     
     
    The Credit Facilities are secured, subject to permitted liens and other agreed upon exceptions, by a first-priority lien on and perfected security interest in substantially all of the Company’s present and future assets (including, without limitation, fee-owned real property).
     
     

     
     
     
    The Credit Agreement contains customary representations, warranties, affirmative and negative covenants (including financial covenants) and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of the Company’s Common Stock and acquisitions, subject in each case to certain exceptions. The Credit Agreement also contains certain financial covenants with respect to minimum fixed charge coverage ratio and maximum cash flow leverage ratio. The Company is required to maintain a minimum fixed charge coverage ratio of 1.10x for all testing periods throughout the term(s) of the Credit Facilities, which calculation excludes certain specified items, unless the Company’s liquidity falls below a specified threshold. The Company is also required to maintain a cash flow leverage ratio of 3.50x or less for all testing periods throughout the term(s) of the Credit Facilities.
     
     
     
    This description of the Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement, which is attached hereto as Exhibit 10.1.
     
     
    Item 2.03
    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
     
     
     
    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.
     
    Item 9.01
    Financial Statements and Exhibits.
     
     
    (d)
    Exhibits.
       
     
     
    EXHIBIT
    NUMBER
    EXHIBIT DESCRIPTION
       
     
     
    10.1*
    Credit Agreement dated February 6, 2025, between National Research Corporation, each lender from time to time party thereto, and First National Bank of Omaha, as Administrative Agent.
     
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     
    * Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish to the Securities and Exchange Commission (“SEC”) a supplemental copy of any omitted schedule or attachment upon request by the SEC.
     
     

     
     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    NATIONAL RESEARCH CORPORATION
     
    (Registrant)
         
    Date: February 10, 2025
    By:
    /s/ Michael D. Hays
       
    Michael D. Hays
       
    Chief Executive Officer
     
     
    Get the next $NRC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • A New Era of Trust: NRC Health's 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience

      NRC Health unveils its 2025 Experience Perspective Report, highlighting new research and trends shaping the future of healthcare, with a focus on trust, generational shifts, and evolving consumer demands. NRC Health, a recognized leader in healthcare experience management solutions to transform interactions for patients, consumers, and employees alike, released its 2025 Experience Perspective today during a live national webcast. Known for delivering premier market research and data-driven insights, NRC Health's report features key findings and strategic recommendations based on extensive research involving millions of consumers, patients, and other healthcare leaders nationwide. Guided b

      4/10/25 2:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Green Trent S was granted 500,000 shares (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      6/3/25 4:47:16 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 3 filed by new insider Green Trent S

      3 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      6/3/25 4:41:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

      4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

      5/13/25 11:30:22 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    SEC Filings

    See more
    • National Research Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/12/25 9:01:47 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by National Research Corporation

      10-Q - NATIONAL RESEARCH CORP (0000070487) (Filer)

      5/9/25 10:02:32 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

      4/28/25 5:12:02 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Financials

    Live finance-specific insights

    See more
    • NRC Health Announces First Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the first quarter 2025 and other corporate developments. Highlights: Total Recurring Value Contract Value Increases Sequentially Sales Force Expansion Accelerates New Share Repurchase Program Announced Operating Expenses Decline Dividend Declared Overview Michael D. Hays, Chief Executive Officer of NRC Health, commented on the Company's performance and recent developments: "The key milestone this quarter was a second consecutive quarter of sequential increase in total recurring contract value, which remains the leading indicator of revenue growth. This progress reflects the rebuilding of o

      4/28/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Declares Quarterly Dividend

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 (twelve cents) per share payable Friday, April 11, 2025, to shareholders of record as of the close of business on Friday, March 28, 2025. For more than 40 years, NRC Health (NASDAQ:NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health's commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health's patient-focuse

      3/24/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • National Research Corporation Announces Fourth Quarter Results

      National Research Corporation, dba NRC Health, (NASDAQ:NRC) today announced results for the fourth quarter 2024 and other corporate developments. Financial Results Revenue for the quarter was approximately $36.9 million compared with approximately $38.0 million in the 2023 quarter. Earnings per diluted share were $0.28 compared with $0.36 for the 2023 quarter. At December 31, 2024, the Company's net indebtedness (total borrowing minus cash and cash equivalents) was approximately $58.5 million. Total recurring contract value (TRCV) was approximately $133.2 million at December 31, 2024. Dividends and Stock Repurchases During the quarter, the Company returned approximately $10.1 millio

      1/27/25 5:00:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by National Research Corporation

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      11/13/24 4:05:19 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by National Research Corporation (Amendment)

      SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/8/24 4:05:05 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by National Research Corporation (Amendment)

      SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

      3/5/24 4:31:31 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    See more
    • National Research Corporation Appoints Trent Green as Chief Executive Officer

      National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

      3/4/25 4:01:00 PM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer

      Baron will align and advance NRC Health's experience solutions platform to solve health care industry challenges and continue effectively innovating and supporting experience improvement for health systems across the nation. NRC Health, a recognized leader providing solutions and data driven insights for improving health care experiences, announced today the appointment of Jennifer Baron as the organization's first chief experience officer. Baron's addition is part of the organization's continued investments in leadership and innovation to align with the evolving healthcare landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho

      4/2/24 11:55:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions

      NRC Health, the leading provider of human-centered healthcare solutions and data-driven insights, is elevating its leadership team with the appointment of four executive-officer positions. The strategic move will allow NRC Health to accelerate innovation while continuing to provide exceptional customer experiences to its partners. Four newly created executive leadership roles will guide NRC Health's strategy and success, including: Helen Hrdy, Chief Customer Officer Jason Hahn, Chief Revenue Officer Christophe Louvion, Chief Product Technology Officer Andy Monnich, Chief Corporate Development Officer "Strong leadership is key in driving innovation and meeting the ever-evolv

      2/1/24 10:00:00 AM ET
      $NRC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care